IAFF Launches Smoking Cessation Campaign with Pfizer

Pfizer Inc.The International Association of Fire Fighters has announced the launch of a new initiative to help fire fighters, family members and friends to quit smoking cigarettes. "Our goal is to help make the IAFF the first smoke-free union," IAFF General President Harold Schaitberger said in his address to delegates at the IAFF 49th Convention.

The IAFF is collaborating with pharmaceutical company Pfizer Inc. to promote smoking cessation. Schaitberger and Pfizer CEO Jeff Kindler first announced the joint initiative at the IAFF Health and Safety Conference in Chicago, Illinois, in October 2007.

The campaign includes materials designed to help fire fighters understand the risks of smoking and provide information on how to quit. These and other resources are available on a new web site at www.iaff.org/smokefree. In the coming weeks, the campaign will add new resources, including a DVD featuring stories from fire fighters about how they quit smoking. The web site and other materials are available to assist IAFF affiliates across North America in reaching out to members, families and communities to promote and encourage smoking cessation.

Smoking is a major health risk for fire fighters who are already at high risk for illnesses, including heart disease, respiratory disease and certain cancers. In addition, smoking is the leading cause of fires and a significant occupational risk for fire fighters.

"We congratulate the IAFF for its commitment to this campaign and look forward to working together toward the goal of a smoke-free union," Kindler said. "Fire fighters are respected leaders in their communities, and this program on smoking cessation reaffirms that leadership."

"Fire fighters place themselves in harm's way, confront dangerous environments, high heat and flames, and exposure to burning materials," Schaitberger said. "It's stressful work and some respond to stress by smoking. Yet smoking increases the health risks fire fighters face. We want to help prevent that."

The International Association of Fire Fighters, headquartered in Washington, DC, represents more than 288,000 full-time professional fire fighters and paramedics who protect 85 percent of the nation's population. More information is available at www.iaff.org.

Pfizer discovers and develops innovative medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality healthcare and health system support.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...